Introduction: Haploidentical donors may resolve the shortage of available HLA-matched donors for
the treatment of blood cancers requiring hematopoietic stem cell transplantation (HSCT).
However, to prevent graft-versus-host disease (GVHD), haploidentical HSCT requires
alloreactive T-cell depletion. We developed a strategy that allows donor lymphocyte
infusion post-HSCT without inducing severe GVHD and maintaining reactivity against
viruses and leukemic cells.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
